2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
267 225 7416
https://www.contexttherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Martin A. Lehr | Co-Founder, Pres, CEO & Director | 523.71k | N/A | 1984 |
Ms. Jennifer Minai-Azary | CFO & Treasurer | 404.33k | N/A | 1978 |
Mr. Alex C. Levit Esq. | Chief Legal Officer & Corp. Sec. | 490.82k | N/A | 1979 |
Dr. Felix Kim Ph.D. | Co-founder & Chair of Scientific Advisory Board | N/A | N/A | N/A |
Mr. Christopher Beck M.B.A. | Sr. VP of Operations | N/A | N/A | N/A |
Dr. Tarek Sahmoud M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1961 |
Dr. Evan G. Dick | Sr. VP of R&D | N/A | N/A | 1952 |
Ms. Elizabeth Nemchik CPA | Controller | N/A | N/A | N/A |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.